Back to Search Start Over

Durability of Humoral Immune Responses to SARS-CoV-2 in Citizens of Ariano Irpino (Campania, Italy): A Longitudinal Observational Study With an 11.5-Month Follow-Up

Authors :
Annachiara Coppola
Carlo Buonerba
Davide Cardinale
Gabriella Lo Conte
Donato Sansone
Giuseppe Rofrano
Sabato De Vita
Maria Morgante
Maria Triassi
Luigi Atripaldi
Gianfranco Brambilla
Rocco Sabatino
Andrea Pierri
Daniela Pacella
Antonio Pizzolante
Biancamaria Pierri
Veronica Ferrucci
Massimo Zollo
Mario Capasso
Silvia Stringhini
Paolo Antonio Ascierto
Sante Roperto
Pellegrino Cerino
Source :
Frontiers in Public Health, Vol 9 (2021)
Publication Year :
2021
Publisher :
Frontiers Media S.A., 2021.

Abstract

As of November 17, 2021, SARS-CoV-2 (Severe Acute Respiratory Syndrome CoronaVirus 2), the causative agent of COVID-19 (COronaVIrus Disease 19), has infected ~250 million people worldwide, causing around five million deaths. Titers of anti-SARS-CoV-2 neutralizing antibodies were relatively stable for at least 9 months in a population-based study conducted in Wuhan, China, both in symptomatic and in asymptomatic individuals. In the mass screening campaign conducted in the town of Ariano Irpino (Avellino, Italy) in May, 2020, 5.7% (95% CI: 5.3-6-1) of the 13,444 asymptomatic citizens screened were positive for anti-nucleocapsid antibodies against SARS-CoV-2. Among these, 422 citizens were re-tested for anti SARS-CoV-2 antibodies in January, 2021 and/or in April, 2021 and enrolled in this longitudinal observational study. Median (interquartile range) age of the study cohort was 46 years (29–59), with 47 (11.1%) participants of minor age, while 217 (51.4%) participants were females. There was no evidence of re-infection in any of the subjects included. Presence of anti-nuclear antibodies antibodies (Elecysis, Roche) was reported in 95.7 and 93.7% of evaluable participants in January and April, 2021. Multiple logistic regression analysis used to explore associations between age, sex and seroprevalence showed that adults vs. minors had significantly lower odds of having anti-S1 antibodies (Biorad) both in January, 2021 and in April, 2021. Our findings showed that antibodies remained detectable at least 11.5 months after infection in >90% of never symptomatic cases. Further investigation is required to establish duration of immunity against SARS-CoV-2.

Details

Language :
English
ISSN :
22962565
Volume :
9
Database :
Directory of Open Access Journals
Journal :
Frontiers in Public Health
Publication Type :
Academic Journal
Accession number :
edsdoj.58570421f438eb6384d79b9c33d7a
Document Type :
article
Full Text :
https://doi.org/10.3389/fpubh.2021.801609